model updat question
wont answer
ahead earn releas updat
sales/ep estim cc organ revenu
recog adj cc organ
om/tax vs prior estim
compar consensu manag
ep guidanc pt unchang remain buy rate
updat estim updat fy sales/ep
estim cc organ revenu recog adj
cc organ revenu
recog adj exhibit forecast gm/om/tax
consensu manag organ
growth guidanc excl impact revenu recog adj ep
rang estim chang larg driven shift
translat fx modestli neg could
partial eras prior anticip per quarter tailwind
look call
interest acquir buy wsj
strateg rational behind acquisit question like
wont answer intrigu combin best class
pma compani link syk abil drive continu
uptak mako robot knee share overal health global hip/kne
market follow soft outlook challeng spine space
progress toward achiev minimum oper leverag
improv promis year driven part progress erp system
unif product life cycl manag initi entellu
physio-control novadaq momentum updat definit agreement
acquir safeair privat includ terms/synergi target expect
close
valuat risk like syk reliabl strong sale growth
diversif well upsid potenti via futur accret
seemingli genuin focu margin improv period
revenu forecast show compound-annual-growth-rate unreason
presum anoth point inorgan growth
continu pg
tr target
use rel valuat framework regress forward sale compound-annual-growth-rate vs rel forward
peer price-to-earnings ascrib rel forward price-to-earnings premium convolv month
averag forward multipl anticip ep month henc arriv
price target supplement strong top-lin like recent enact manag
incent gear improv oper margin assum improv
around earn risk target price includ inabl mako drive share
gain hospit capital-expenditure declin failur deliv promis margin expans and/or maintain
due acquisit misstep and/or downward reset recent market multipl
earn call juli pm et dial-in id
page
exhibit revenu varianc segment product categori
page
strh estimatesactualconsensusno ofstrh vs consensu cc pt handl emerg spineneurotechnolog neurotechnolog total stryker corpor
page
exhibit revenu varianc segment product categori
page
strh estimatesstrhconsensusno ofstrh vs consensu cc pt handl emerg spineneurotechnolog neurotechnolog total stryker corpor
page
page
therapytot incom inc med-tech w/ analysisgross analysissal cc sd cc extrem orthoped total neurotech spine ep stryker corpor
global compani provid medic technolog product servic busi
segment orthoped medsurg neurotechnolog spine compani found
homer stryker incorpor headquart kalamazoo mi
believ strength brand us compani proven abil maxim
impact acquir technolog busi upon incorpor syk excel commerci
organ support target price
valuat risk
like syk reliabl strong sale growth diversif well upsid potenti via futur
accret seemingli genuin focu margin improv period
revenu forecast show compound-annual-growth-rate unreason presum anoth point
inorgan growth use rel valuat framework regress forward sale compound-annual-growth-rate
vs rel forward peer price-to-earnings ascrib rel forward price-to-earnings premium convolv
month averag forward multipl anticip ep month
henc arriv price target supplement strong top-lin like recent enact
manag incent gear improv oper margin assum
improv around earn risk target price includ inabl mako
drive share gain hospit capital-expenditure declin failur deliv promis margin expans and/or
maintain due acquisit misstep and/or downward reset recent market multipl
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
